{"entity":{"id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","aka":[],"tldr":"A phase 1/2 trial of Will receive HH-009 injection 20 mg/kg, Q3W in hepatocellular carcinoma, run by Huahui Health, now recruiting.","summary":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC is a phase 1/2 interventional study registered as NCT07547553 by Huahui Health, with 30 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-10-30. Interventions recorded: Will receive HH-009 injection 20 mg/kg, Q3W and Will receive HH-009 injection 30 mg/kg, Q3W.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07547553","url":"https://clinicaltrials.gov/study/NCT07547553"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07547553","phase":"1/2","setting":"A Randomized, Open-Label, Multicenter, Phase Ib/II Registration Trial to Observe and Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HH-009 Injection in FGF19-Positive Participants With Advanced or Unresectable Hepatocellular Carcinoma (HCC) Who Have Experienced Progressive Disease After Prior Systemic Therapy","sponsor":"Huahui Health","enrolled":30,"outcomes":[]},"route":"/trials/nct07547553/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}